Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of treatment strategies for patients with myelofibrosis (MF), highlighting the importance of novel JAK inhibitors and the promise of combination approaches. Dr Verstovsek also comments on the potential application of cellular therapies and vaccines in the future. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
